Intech Investment Management LLC Invests $160,000 in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 13,052 shares of the company’s stock, valued at approximately $160,000.

A number of other institutional investors also recently modified their holdings of STOK. Quest Partners LLC bought a new stake in Stoke Therapeutics in the second quarter valued at $29,000. Nisa Investment Advisors LLC increased its position in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after buying an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $123,000. The Manufacturers Life Insurance Company raised its stake in Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares during the period. Finally, Profund Advisors LLC bought a new position in Stoke Therapeutics in the second quarter worth approximately $201,000.

Insider Transactions at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares in the company, valued at $125,131,843.05. The trade was a 17.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares in the company, valued at $618,913.39. The trade was a 16.32 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on STOK. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Stock Performance

STOK stock opened at $13.27 on Friday. The company has a market capitalization of $702.91 million, a P/E ratio of -6.32 and a beta of 0.95. Stoke Therapeutics, Inc. has a 52-week low of $4.09 and a 52-week high of $17.58. The business has a 50-day simple moving average of $12.41 and a two-hundred day simple moving average of $13.71.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.